磁共振成像靶向活检对前列腺切除术后病理升级与降级的影响:系统评价与Meta分析
该系统评价与Meta分析检索2018年7月至2022年1月PubMed MEDLINE和Cochrane Library,纳入同时行系统穿刺和MRI靶向穿刺并与前列腺切除术后病理对照的研究。结果显示,仅靶向穿刺和联合穿刺较系统穿刺均降低病理升级风险(OR 0.70和0.50),但增加降级风险(OR 1.24和1.96);联合穿刺较系统穿刺在切除术后降级率更高(19% vs 11%),而升级率更低(27% vs 42%)。异质性明显。
要点
- 仅靶向穿刺和联合穿刺较系统穿刺均降低前列腺切除术后病理升级风险(OR 0.70和0.50)。
- 仅靶向穿刺和联合穿刺较系统穿刺均增加降级风险(OR 1.24和1.96)。
- 联合穿刺较系统穿刺在切除术后降级率更高(19% vs 11%),升级率更低(27% vs 42%)。
核心结论
- 与系统穿刺相比,加入MRI靶向穿刺可降低前列腺切除术后病理升级率(27% vs 42%),但联合MRI靶向与系统穿刺与更多降级相关(19% vs 11%)。
- 研究间异质性明显,需要进一步研究影响升级和降级率的因素,并区分临床相关与不相关的分级变化。
- 在此之前,联合MRI靶向与系统穿刺的获益与危害尚无法完全评估。
研究设计与样本
- 系统评价与Meta分析,检索PubMed MEDLINE和Cochrane Library自2018年7月至2022年1月。
- 纳入同时行系统穿刺和MRI靶向穿刺并与根治性前列腺切除术后病理对照的研究。
主要发现
- 仅靶向穿刺较系统穿刺降低升级风险(OR 0.70,95%CI 0.63-0.77,p<0.001)。
- 联合穿刺较系统穿刺降低升级风险(OR 0.50,95%CI 0.45-0.55,p<0.001)。
- 仅靶向穿刺较系统穿刺增加降级风险(OR 1.24,95%CI 1.05-1.46,p=0.012)。
- 联合穿刺较系统穿刺增加降级风险(OR 1.96,95%CI 1.68-2.27,p<0.001)。
- 若认为升级与降级危害相等,靶向穿刺和联合穿刺的净获益为每100例中8例和7例;若认为降级危害为升级的两倍,则净获益为每100例中7例和-1例。
关键数值与推荐
- 仅靶向穿刺与系统穿刺相比:升级OR 0.70(95%CI 0.63-0.77,p<0.001),降级OR 1.24(95%CI 1.05-1.46,p=0.012)。
- 联合穿刺与系统穿刺相比:升级OR 0.50(95%CI 0.45-0.55,p<0.001),降级OR 1.96(95%CI 1.68-2.27,p<0.001)。
- 联合穿刺与系统穿刺相比:升级率27% vs 42%,降级率19% vs 11%。
临床怎么用
- 原文结论指出,联合MRI靶向与系统穿刺的获益与危害尚无法完全评估,需进一步研究影响分级变化的因素。
局限性
- 研究间存在明显异质性,提示需要进一步研究影响升级和降级率的因素,并区分临床相关与不相关的分级变化。
- 在进一步研究之前,联合MRI靶向与系统穿刺的获益与危害无法完全评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The evidence supporting multiparametric magnetic resonance imaging (MRI) targeting for biopsy is nearly exclusively based on biopsy pathologic outcomes. This is problematic, as targeting likely allows preferential identification of small high-grade areas of questionable oncologic significance, raising the likelihood of overdiagnosis and overtreatment. OBJECTIVE: To estimate the impact of MRI-targeted, systematic, and combined biopsies on radical prostatectomy (RP) grade group concordance. EVIDENCE ACQUISITION: PubMed MEDLINE and Cochrane Library were searched from July 2018 to January 2022. Studies that conducted systematic and MRI-targeted prostate biopsies and compared biopsy results with pathology after RP were included. We performed a meta-analysis to assess whether pathologic upgrading and downgrading were influenced by biopsy type and a net-benefit analysis using pooled risk difference estimates. EVIDENCE SYNTHESIS: Both targeted only and combined biopsies were less likely to result in upgrading (odds ratio [OR] vs systematic of 0.70, 95% confidence interval [CI] 0.63-0.77, p < 0.001, and 0.50, 95% CI 0.45-0.55, p < 0.001), respectively). Targeted only and combined biopsies increased the odds of downgrading (1.24 (95% CI 1.05-1.46), p = 0.012, and 1.96 (95% CI 1.68-2.27, p < 0.001) compared with systematic biopsies, respectively. The net benefit of targeted and combined biopsies is 8 and 7 per 100 if harms of up- and downgrading are considered equal, but 7 and -1 per 100 if the harm of downgrading is considered twice that of upgrading. CONCLUSIONS: The addition of MRI-targeting results in lower rates of upgrading as compared to systematic biopsy at RP (27% vs 42%). However, combined MRI-targeted and systematic biopsies are associated with more downgrading at RP (19% v 11% for combined vs systematic). Strong heterogeneity suggests further research into factors that influence the rates of up- and downgrading and that distinguishes clinically relevant from irrelevant grade changes is needed. Until then, the benefits and harms of combined MRI-targeted and systematic biopsies cannot be fully assessed. PATIENT SUMMARY: We reviewed the ability of magnetic resonance imaging (MRI)-targeted biopsies to predict cancer grade at prostatectomy. We found that combined MRI-targeted and systematic biopsies result in more cancers being downgraded than systematic biopsies.
引用
- Weinstein IC, Wu X, Hill A, et al. Impact of Magnetic Resonance Imaging Targeting on Pathologic Upgrading and Downgrading at Prostatectomy: A Systematic Review and Meta-analysis. Eur Urol Oncol. 2023. PMID: 37236832. doi:10.1016/j.euo.2023.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。